![]() |
|
|
May 2008 |
|
To view past issues of the Securities Update, please visit http://business.cch.com/updates/securities If you have questions or comments concerning the information provided below, please contact me at rodney.tonkovic@wolterskluwer.com.
CCH Federal Securities Law ReporterAmendments to Form S-11 Expand Incorporation by ReferenceThe SEC adopted amendments to Form S-11, the registration statement used by real estate entities to register offerings under the Securities Act. The amendments permit an entity that has filed an annual report and that is current in its reporting obligations under the Exchange Act to incorporate by reference into Form S-11 information from its previously filed Exchange Act reports and documents. The amendments are identical to amendments to Form S-1 and Form F-1 previously adopted by the Commission in the 2005 offering reform rulemaking. Release No. 33-8809 at ¶88,092 (ip access user).
SEC Adopts Amendments to Implement
Sudan Divestment Act
SEC Adopts Technical Amendments to
“Broker” Exceptions for Banks
Fraud Claims Revived Under Tellabs
Analysis: 1st Circuit A plaintiff class sued Boston Scientific, a medical device manufacturer, for securities fraud under four distinct allegations of securities fraud. The investor class claimed inadequate and misleading disclosures regarding 1) a civil fraud and contract lawsuit with another manufacturer, 2) a Department of Justice investigation into a 1998 product recall, 3) the company's introduction of TAXUS stents to the market, and 4) FDA investigations and warnings regarding Boston Scientific's plants. Only the TAXUS stent issue was before the court on appeal following the dismissal of all claims. The class made several allegations concerning problems with the company's stent device. As alleged, the company knew of and did not reveal problems with the device from its use in Europe prior to its U.S. introduction, and the company's failure to disclose an FDA deficiency letter. The company also did not disclose a change in its manufacturing process, and according to the class complaint, the defendants misleadingly attributed any risks or problems to the unfamiliarity of doctors with the new device rather than to any functionality issues. This delay in addressing functionality evidenced scienter, according to the complaint, because of the desire of the defendants to build up inventory before announcing product recalls. The district court dismissed all claims, finding in a pre-Tellabs decision that the allegations represented at most fraud by hindsight. "[N]o liability exists where a plaintiff's claim rests on the assumption that the defendants must have known of the severity of their problems earlier because conditions became so bad later on," wrote the trial court. The 1st Circuit rejected this conclusion, however, because the district court failed to consider other allegations that the lead plaintiff made in its supporting documents. The panel found, applying Tellabs, that "while there is support for defendants' inferences, we think, at this stage, that plaintiff's inferences are at least equally strong." In re Boston Scientific Corp. Securities Litigation (1stCir) is reported at ¶94,645.
The U.S. Supreme Court recognized the doctrine of directors by deputization in the 1962 decision. The high court found that a shareholder, such as a partnership or corporation, could be a director for Section 16 purposes "if the investor actually functioned as a director" and "had been deputized to perform a director's duties not for himself" but for the firm. The appeals court also rejected the plaintiff's contention that the Rule 16b-3(d) exemption is inapplicable to a director by deputization that is also a 10 percent holder. The court noted that "the Commission's adopting release, however, specifically addresses the rule's application to ten percent holders who are directors, and it does so without drawing a distinction between named directors and directors by deputization." In that release, the SEC stated that Rule 16b-3 does not provide an exemption for persons who are subject to section 16 solely because they beneficially own greater than ten percent of a class of an issuer's equity securities. Roth v. Perseus, L.L.C (2ndCir) is reported at ¶94,644.
Whistleblower’s Complaints Not
Protected Under Sarbanes-Oxley The district court (MD NC) entered summary judgment, concluding that the employee's complaints were not protected activity under the Sarbanes-Oxley Act because he could not reasonably have believed that the company was violating the securities laws. The court also concluded that the company had shown that the employee was discharged for insubordination and that the employee would have been discharged regardless of whether he had complained about the progress of the training program. A panel of the 4th Circuit Court of Appeals affirmed, based on the conclusion that no objectively reasonable basis existed for the employee to have believed that the company was violating the securities laws. The court noted that the employee did not complain that the company ever made any false statements to government agencies or stockholders, and the company in fact never did so. Furthermore, the training program was completed on schedule. According to the court, the employee failed to produce evidence that he provided information or made a complaint to the company about conduct which a reasonable employee in his position could have believed at the time constituted a violation of the securities laws. The employee failed to show that the company misrepresented or concealed anything, violated a consent decree, had or intended to mislead shareholders, or that deficiencies in the training program schedule had a material impact on the company's finances. The court summed up by saying that "not one link in [the employee's] imaginary chain of horribles was real or was in the process of becoming real." Livingston v. Wyeth, Inc. (4thCir) is reported at ¶94,614 (ip access user) CCH Blue Sky Law Reporter
California Amends Broker-Dealer Recordkeeping
and BD/IA Financial Reporting Amendments Mississippi Clarifies Federal Covered
Securities Rules and Adopts NASAA IA Recordkeeping and Custody Model Rules
and NASAA Policy on Internet Advertising Washington Proposes Amendments to its
Regulation D Rules Wisconsin Adopts Uniform Securities
Act of 2002 Agent Registration Required for Sellers
of Covered Securities Aspen Federal Securities PublicationsA Practical Guide to SEC Proxy and
Compensation Rules, Fourth Edition, edited by Amy L. Goodman, John F.
Olson, and Lisa A Fontenot Hot Topic of the Month
This month's hot topic is the Whistleblower Protection provisions of the Sarbanes Oxley Act. Sections 806 and 1107 of the Act created new federal protections designed to shield whistleblowers from retaliation. Section 806 prohibits certain retaliatory action against employees and Section 1107 establishes a criminal penalty for retaliation against a whistleblower. Section 806 forbids public companies from taking retaliatory action against employees who provide information or assist in the investigation of conduct they reasonably believe is a securities violation or securities fraud, or who file or participate in proceedings related to fraud against shareholders. The protections only apply to investigations conducted by a federal regulator or law enforcement agency, a member of Congress or a congressional committee, or the employee's supervisor; employee complaints to the news media, by themselves, do not constitute whistleblowing under the Act. The aggrieved employee may bring a civil action for violations. Criminal penalties are contained in Section 1107 of the statute and apply to a much broader set of whistleblowing transgressions than just those relating to securities fraud. A retaliatory action becomes a criminal matter under Section 1107 if the employee provides information to a law enforcement officer concerning the commission of any federal offense. Section 1107 states that whoever knowingly, with the intent to retaliate, takes any action harmful to any person for providing to a law enforcement officer any truthful information relating to the commission or possible commission of any federal offense, must be fined or imprisoned for up to 10 years, or both. Sarbanes-Oxley primarily placed enforcement of the whistleblower provision with the Department of Labor. If the Department of Labor does not resolve the matter within a specified period of time, the aggrieved whistleblower may bring an action in federal court. To date, the Commission has neither proposed rules concerning Section 806 nor filed an enforcement action under the statute. The SEC has relied on OSHA's efforts when it comes to the prosecution of stand-alone violations of the whistleblower protection provisions. The Chairman of the SEC has stated that to the extent that a company retaliates against an employee for blowing the whistle on practices that constitute violations of the securities laws, the SEC would investigate and bring an enforcement action against the company for any substantive violations. We publish related information in a wide range of resources (e.g., Federal Securities Law Reporter, SEC Today, Insights – Amy L. Goodman, Securities Regulation – Loss, Seligman & Paredes, etc.), and document types (laws, regulations, releases, newsletter articles, treatise discussion). For example: SEC Today
Federal Securities Law Reporter
Insights – Amy L. Goodman
(e.g., “The Whistleblower Provisions of the Sarbanes-Oxley Act of
2002” (December
2002) (ip
access user) IPO Vital SignsIPO Vital Signs, an advanced IPO research analysis tool, assists IPO professionals and pre-IPO companies satisfy their most challenging research needs and answers hundreds of mission critical questions for all the players in the IPO process. IPO Vital Signs’ tabular data analyses focus on issues surrounding client advisement, deal negotiation, and prospectus disclosure. IPO Week in Review, a weekly e-newsletter to keep professionals up to date with recent filing and going public activity, is an important element of the IPO Vital Signs system or is available by separate subscription. Coverage includes a monthly feature article on recent trends in going public in the U.S. To see how an IPO Vital Sign works click on the Vital Sign title below: Use IPO Vital Sign #770 to…
and drill down into the different management listings to see
Tip! Click on blue numbers to drill down for more information.
|